ALIM Jul 2024 2.500 call
| Previous close | 2.2000 |
| Open | N/A |
| Bid | 0.0000 |
| Ask | 5.0000 |
| Strike | 2.50 |
| Expiry date | 2024-07-19 |
| Day's range | 2.2000 - 2.2000 |
| Contract range | N/A |
| Volume | |
| Open interest | 6 |
GlobeNewswireAlimera Sciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ATLANTA, June 04, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera” or the “Company”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health, and maintaining better vision longer, today announced that, pursuant to Nasdaq Listing Rule 5635(c)(4) and in connection with the appointments of five non-executive employees, the Compensation Committee of the Board of Directors of the Company (the “Comp
- GuruFocus.com
Alimera Sciences Inc (ALIM) Q1 2024 Earnings Call Transcript Highlights: Soaring Revenues and ...
Discover how Alimera Sciences achieved remarkable revenue growth and strategic advancements in Q1 2024.
ZacksAlimera Sciences (ALIM) Reports Q1 Loss, Misses Revenue Estimates
Alimera Sciences (ALIM) delivered earnings and revenue surprises of -200% and 2.99%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
